Valve-in-Valve Transcatheter Aortic Valve Replacement, with Present-Day Innovations and Up-to-Date Techniques

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology
• Biomedical Engineering

Background:

• Surgical aortic valve replacement (SAVR) is performed annually in 51,000-65,000 US cases.
• Bioprosthetic degeneration occurs within 10-15 years, necessitating approximately 800 redo SAVR procedures yearly.
• Redo SAVR carries significant risks for patients.

Purpose of the Study:

• To review the current evidence and clinical application of valve-in-valve transcatheter aortic valve replacement (ViV TAVR).
• To highlight procedural planning, technical considerations, and potential complications associated with ViV TAVR.
• To discuss the long-term follow-up and outcomes of ViV TAVR for failed bioprosthetic valves.

Main Methods:

• Review of existing literature on ViV TAVR procedures.
• Analysis of FDA approval timelines for self-expanding and balloon-expandable valves for ViV TAVR.
• Examination of case studies and clinical trial data regarding ViV TAVR outcomes.

Main Results:

• ViV TAVR is an FDA-approved, safe, and effective alternative for high-risk patients with failed surgical valves.
• Successful ViV TAVR implementation requires meticulous procedural planning and awareness of technical challenges.
• Long-term follow-up data indicate favorable outcomes and durability for ViV TAVR.

Conclusions:

• ViV TAVR represents a significant advancement in managing degenerated bioprosthetic aortic valves.
• Careful patient selection and procedural execution are crucial for optimizing ViV TAVR results.
• ViV TAVR provides a valuable option for patients previously facing high-risk redo surgery.